Literature DB >> 17690854

Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).

M Capobianco1, S Malucchi, A di Sapio, F Gilli, A Sala, R Bottero, F Marnetto, C Doriguzzi Bozzo, A Bertolotto.   

Abstract

We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17690854     DOI： 10.1007/s10072-007-0823-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  10 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays.

Authors:  P H Lalive; T Menge; I Barman; B A Cree; C P Genain
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

3.  Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

Authors:  Bianca Weinstock-Guttman; Murali Ramanathan; Norah Lincoff; Salvatore Q Napoli; Jitendra Sharma; Joan Feichter; Rohit Bakshi
Journal:  Arch Neurol       Date:  2006-07

4.  An open label study of the effects of rituximab in neuromyelitis optica.

Authors:  B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

8.  Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.

Authors:  Angelo Ghezzi; Roberto Bergamaschi; Vittorio Martinelli; Maria Trojano; M Rosaria Tola; Elisa Merelli; Luigi Mancardi; Paolo Gallo; Massimo Filippi; Mauro Zaffaroni; Giancarlo Comi
Journal:  J Neurol       Date:  2004-01       Impact factor: 4.849

9.  Neuromyelitis Optica.

Authors:  Dean M Wingerchuk; Brian G Weinshenker
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307
  10 in total
  17 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

2.  Immune agents for the treatment of Devic's neuromyelitis optica.

Authors:  R Bergamaschi
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

Review 3.  Update on neuromyelitis optica: natural history and management.

Authors:  Panitha Jindahra; T Plant
Journal:  Eye Brain       Date:  2012-03-26

Review 4.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

5.  Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

Authors:  Romain Marignier; Pascale Giraudon; Sandra Vukusic; Christian Confavreux; Jérôme Honnorat
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

6.  Current and future treatment approaches for neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

7.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Authors:  Norio Chihara; Toshimasa Aranami; Wakiro Sato; Yusei Miyazaki; Sachiko Miyake; Tomoko Okamoto; Masafumi Ogawa; Tatsushi Toda; Takashi Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

Review 8.  An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2016-03-23       Impact factor: 6.570

Review 9.  Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

Authors:  Bruce Cree
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

10.  Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.

Authors:  Pietro Annovazzi; M Capobianco; L Moiola; F Patti; J Frau; A Uccelli; D Centonze; P Perini; C Tortorella; L Prosperini; G Lus; A Fuiani; M Falcini; V Martinelli; G Comi; A Ghezzi
Journal:  J Neurol       Date:  2016-06-10       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.